PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

RSS icon
Researchers working to develop portable PET scanner

Researchers receive grant worth millions to develop portable PET scanner

Experts are hopeful that the portable scanner could improve access to neuroimaging used in the diagnosis and monitoring of Alzheimer's disease.

Georgia Lawrence, JD, with ASNC, explains how CMS uses hospital reported data to develop cardiac PET payment rates.

Understanding hospital billing for cardiac PET/CT

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

Gila monster saliva helps docs detect insulinomas.

Lizard saliva could be key to spotting elusive pancreatic tumors

By binding the substance to a radiotracer, experts were able to improve the accuracy of identifying these tumors by as much as 30% compared to the standard of care.

The new cardiac PET radiotracer flurpiridaz F-18 is posed to be a major game changer and will likely lead to increased adoption of cardiac PET.

FDA approves GE HealthCare's flurpiridaz F-18 PET radiotracer for CAD

The newly approved radiotracer is seen as a major step forward for nuclear imaging technology. Specialists have been looking forward to its arrival on the market for quite some time.

Thumbnail

Novel radiotracer could improve the diagnosis of interstitial lung disease

Researchers are hopeful that uptake of the molecular SPECT imaging agent will help providers more ably monitor disease progression.

New PET technique improves imaging of pediatric neuroblastoma.

New PET technique slashes scan times, improves image quality in neuroblastoma cases

The method also reduces radiation doses and eliminates the need for sedation or general anesthesia.

Thumbnail

'Game changer' prostate imaging agent granted FDA's Fast Track designation

The PET agent was developed for men with PSMA-positive lesions who have suspected metastasis and are candidates for initial definitive therapy.

FAPI PET improves staging and clinical management for a significant portion of pancreatic cancers

Fibroblast activation protein inhibitor PET imaging may provide more accurate insight into the spread of pancreatic cancer than more commonly used 18F-FDG PET/CT.

Displaying 33 - 40 of 143
Design by Adaptive Theme